T2DM, which presents with hyperinsulinemia at an early stage, is treated by OHAs aimed at promoting insulin sensitivity [10], preventing glucose absorption in the intestines, and stabilizing post-prandial glucose levels [11]. The gene discussed is INS; the disease is type 2 diabetes mellitus.